What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary Biliary Cholangitis
- Main trialPhase 2
- “The goal of this clinical study is to learn more about the combination of study drugs seladelpar and cilofexor. The study will assess, the safety, tolerability, and effectiveness of the combination drugs versus both seladelpar alone and placebo, in participants with primary biliary cholangitis (PBC). The primary objective of this study is to determine whether the combination of seladelpar + cilofexor leads to greater alkaline phosphatase (ALP) reduction than seladelpar alone and describe the safety and tolerability of seladelpar + cilofexor.”In the company’s words, NCT07841977 on ClinicalTrials.gov
- Other names
- CILO · GS-9674
Other drugs for Primary Biliary Cholangitis
- ElafibranorIpsen · Phase 3
- Saroglitazar MagnesiumZydus Therapeutics Inc. · Phase 3
- LinerixibatGSK · Phase 3
- SeladelparGilead (Kite) · Phase 3
- VolixibatMirum Pharmaceuticals, Inc. · Phase 2
- TH104Tharimmune Inc · Phase 2
Coming up1
- Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2028 | Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis | |
| Phase 3Terminated | 10 Nov 2022 | Study of Cilofexor in Adults With Primary Sclerosing Cholangitis | |
| Phase 2Completed | 28 Feb 2018 | Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis | |
| Phase 2Completed | 13 Jul 2020 | Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | |
| Phase 2Completed | 17 Dec 2020 | Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) | |
| Phase 1Completed | 16 Oct 2018 | Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function | |
| Phase 1Terminated | 2 Sep 2021 | Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026